These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Flagellin is a Th1 polarizing factor for human CD4 Labastida-Conde RG; Ramírez-Pliego O; Peleteiro-Olmedo M; Lopez-Guerrero DV; Badillo-Godinez OD; Gutiérrez-Xicoténcatl ML; Rosas-Salgado G; González-Fernández Á; Esquivel-Guadarrama FR; Santana MA Vaccine; 2018 Jul; 36(29):4188-4197. PubMed ID: 29891347 [TBL] [Abstract][Full Text] [Related]
44. A short report on clinical evaluation of RIX4414: highlights of world-wide development. De Vos B; Delem A; Hardt K; Bock HL; Meurice F; Innis B Vaccine; 2006 May; 24(18):3777-8. PubMed ID: 16584814 [No Abstract] [Full Text] [Related]
45. Evaluation of oral Lanzhou lamb rotavirus vaccine via passive transfusion with CD4(+)/CD8(+) T lymphocytes. Du J; Lan Z; Liu Y; Liu Y; Yu Q; Li Y; Guo T Virus Res; 2016 Jun; 217():101-6. PubMed ID: 27025573 [TBL] [Abstract][Full Text] [Related]
46. Foreword: ESPID/ESPGHAN evidence-based recommendations for rotavirus vaccination in Europe. Vesikari T J Pediatr Gastroenterol Nutr; 2008 May; 46 Suppl 2():v-vi. PubMed ID: 18460975 [No Abstract] [Full Text] [Related]
48. Use of rotavirus vaccines in preterm babies on the neonatal unit. Kilich E; Sadarangani M Expert Rev Vaccines; 2016 Dec; 15(12):1463-1465. PubMed ID: 27454209 [No Abstract] [Full Text] [Related]
50. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. Steele AD; Cunliffe N; Tumbo J; Madhi SA; De Vos B; Bouckenooghe A J Infect Dis; 2009 Nov; 200 Suppl 1():S57-62. PubMed ID: 19817615 [TBL] [Abstract][Full Text] [Related]
51. B-Cell-Deficient and CD8 T-Cell-Depleted Gnotobiotic Pigs for the Study of Human Rotavirus Vaccine-Induced Protective Immune Responses. Wen K; Bui T; Weiss M; Li G; Kocher J; Yang X; Jobst PM; Vaught T; Ramsoondar J; Ball S; Clark-Deener S; Ayares D; Yuan L Viral Immunol; 2016 Mar; 29(2):112-27. PubMed ID: 26824402 [TBL] [Abstract][Full Text] [Related]
52. Mechanisms of protection against rotavirus in humans and mice. Ward RL J Infect Dis; 1996 Sep; 174 Suppl 1():S51-8. PubMed ID: 8752291 [TBL] [Abstract][Full Text] [Related]
53. Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial. Bernstein D Pediatrics; 2008 Jan; 121(1):223; author reply 223-4. PubMed ID: 18166579 [No Abstract] [Full Text] [Related]
56. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. De Vos B; Han HH; Bouckenooghe A; Debrus S; Gillard P; Ward R; Cheuvart B Pediatr Infect Dis J; 2009 Apr; 28(4):261-6. PubMed ID: 19289978 [TBL] [Abstract][Full Text] [Related]
57. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. El-Attar L; Oliver SL; Mackie A; Charpilienne A; Poncet D; Cohen J; Bridger JC Vaccine; 2009 May; 27(24):3201-8. PubMed ID: 19446192 [TBL] [Abstract][Full Text] [Related]
58. Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Clarke E; Desselberger U Mucosal Immunol; 2015 Jan; 8(1):1-17. PubMed ID: 25465100 [TBL] [Abstract][Full Text] [Related]
59. Rotavirus vaccines - success after failure. Dennehy PH Med Health R I; 2007 Oct; 90(10):321-4. PubMed ID: 18019190 [No Abstract] [Full Text] [Related]
60. Update on rotavirus trends and the importance of surveillance. Desai SN; Vázquez M Pediatr Infect Dis J; 2010 Dec; 29(12):1130-2. PubMed ID: 21099653 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]